Vaccine-induced thrombotic thrombocytopenia (VITT), a condition characterised by blood clots resulting from COVID-19 vaccinations, is a rare but serious concern in the fight against COVID-19. This Q&A with Dr Ng Heng Joo, Head & Senior Consultant in the Department of Haematology at Singapore General Hospital, explores the pathophysiology, diagnosis of VITT and clinical management of patients on anticoagulation therapy.

• [0:07] – Dr Ng’s current roles
• [0:57] – How VITT differs from other types of blood clots
• [2:08] – Pathophysiology of VITT
• [3:41] – Biomarkers for VITT diagnosis
• [4:49] – Key considerations for anti-PF4 testing
• [8:25] – Key research efforts to understand VITT
• [9:54] – Patient risk factors for VITT
• [10:50] – Risk for patients with history of blood clots
• [12:21] – Considerations for patients on anticoagulation therapy
• [13:25] – Risk for patients with history of venous thromboembolism
• [14:33] – Risk for vaccinating recovered COVID-19 patients
• [15:42] – Management of patients on anticoagulation therapy
• [19:23] – Impact of pandemic on patient anticoagulation journey
• [21:06] – Importance of COVID-19 vaccination efforts

Watch the full Q&A below (click the buttons on the play bar to jump to any specific segment that interests you). Now available with English subtitles.